

MPAC meeting 5- 7 March 2015

Declaration of Interests

All MPAC members participating in the meeting updated their declaration of interest, which was assessed by the WHO Secretariat.

Ten members reported relevant interests, which are summarized below.

Of note, five MPAC members (Salim Abdulla, Brian Greenwood, Kevin Marsh, Laurence Slutsker, and Marcel Tanner) have declared their involvement in the RTS,S Phase 3 trial. They will be allowed to participate in the update on the RTS,S vaccine (Session 8 of the meeting, for discussion). However, they will be recused from the meeting room during the part of the session that is for advice. Any MPAC member with a personal, specific, or financially significant interest in the RTS,S vaccine will have no involvement in decision-making related to policy for RTS,S.

Similarly, one MPAC member (Neena Valecha) whose research institution receives significant funding from insecticide and LLIN manufacturers will be recused from Session 5 (the update from the Vector Control Advisory Group) as the session is for advice.

All reported relevant interests by MPAC members are summarized below:

Salim Abdulla

Is director of the Ifakara Health Institute, which receives research funding from MVI and MMV. This interest was assessed as non-personal, specific and financially significant.*

Fred Binka

Receives research support from the Bill & Melinda Gates Foundation for the InDepth Network Effectiveness and Safety Studies (INESS). This interest was assessed as non-personal, non-specific and financially significant.*

Brian Greenwood

Receives research funding from the Malaria Vaccine Initiative for the RTS,S vaccine trial. This interest was assessed as non-personal, specific, and financially significant.*

Rose Leke

Received funding from Pfizer and the National Institute of Allergy and Infectious Diseases (NIAID), USA for malaria data monitoring and for IPTp. This interest was assessed as non-personal, non-specific and financially significant.*

Kevin Marsh

Is on the malaria vaccines advisory group for USAID, is a PI on the Phase 3 RTS,S study and a collaborator on a Phase 2 malaria vaccine study. This interest was assessed as non-personal, specific, and financially significant.*

Sylvia Meek

Is technical director of the Malaria Consortium which receives research funding from the Bill & Melinda Gates Foundation, DfID, and CDC. This interest was assessed as being non-personal, non-specific, and financially significant.*

Allan Schapira

Received malaria consultancy fees from GHTech, World Bank, and UNDP. This interest was assessed as being personal, non-specific, and financially significant.*

Laurence Slutsker

Receives research support from MVI. This interest was assessed as personal, specific and not financially significant.*

Marcel Tanner

Directs the Swiss Tropical and Public Health Institute which receives research funding from Novartis Institute for Tropical Diseases, SNF, Wellcome Trust, Malaria Vaccine Initiative and the Bill & Melinda Gates Foundation. This interest was assessed to be non-personal, specific, and financial significant.*

Neena Valecha

Directs the National Institute of Malaria Research - New Delhi, which receives research funding from the company Bestnet. This interest was assessed to be non-personal, specific and financially significant.*

*According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single malaria-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one malaria-related company in excess of 1,000 USD would also constitute a "significant shareholding".

Last updated: 03 March 2015